Recently, neuroendocrine lineage plasticity enabled by the loss of TP53 and RB1 function was shown in prostate cancer, mediated by increased expression of the reprogramming transcription factor SOX2 [45]. The gene discussed is RB1; the disease is prostate carcinoma.